We are live on ! Find out more
OFM

Omega Fund Management Portfolio holdings

AUM $163M
1-Year Est. Return 107.06%
This Fund
S&P 500
This Quarter Est. Return
-8.43%
1 Year Est. Return
+107.06%
3 Year Est. Return
+111.75%
5 Year Est. Return
+84.24%
10 Year Est. Return
+495.59%
AUM
$135M
AUM Growth
-$20M
Cap. Flow
+$1.13M
Cap. Flow %
0.83%
Top 10 Hldgs %
99.72%
Holding
12
New
1
Increased
–
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
ALMS
Alumis Inc
ALMS
+$8.69M

Top Sells

Rank Stock Value
1
REPL icon
Replimune Group
REPL
+$3.76M
2
NUVB icon
Nuvation Bio
NUVB
+$2.43M
3
KRON
Kronos Bio
KRON
+$1.24M
4
ENGNW icon
enGene Therapeutics Warrants
ENGNW
+$126K

Sector Composition

Rank Sector Weight
1 Healthcare 99.72%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NUVB icon
1
Nuvation Bio
NUVB
$2.24B
$38.8M 28.72%
13,275,884
-796,456
-6% -$2.43M
LXEO icon
2
Lexeo Therapeutics
LXEO
$366M
$37.8M 28%
2,355,904
– –
REPL icon
3
Replimune Group
REPL
$814M
$22.2M 16.41%
2,461,319
-540,000
-18% -$3.76M
ENGN icon
4
enGene Therapeutics
ENGN
$122M
$10.2M 7.52%
1,076,357
– –
ALMS
5
Alumis Inc
ALMS
$3.57B
$8.69M 6.44%
+653,225
New +$8.69M
MORF
6
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$5.45M 4.03%
159,846
– –
SANA icon
7
Sana Biotechnology
SANA
$885M
$4.61M 3.41%
843,750
– –
IMA
8
ImageneBio Inc
IMA
$63.1M
$3.71M 2.75%
187,427
– –
IMUX icon
9
Immunic
IMUX
$182M
$1.98M 1.47%
178,816
– –
SYRS
10
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.3M 0.96%
251,270
– –
ENGNW icon
11
enGene Therapeutics Warrants
ENGNW
$3.75M
$383K 0.28%
321,502
-39,401
-11% -$126K
KRON
12
DELISTED
Kronos Bio
KRON
– –
-955,866
Closed -$1.24M

Similar funds

HCCM
Hudson Canyon Capital Management New York $163M AUM 33.71% 1-Year Est. Return
PBO
Peoples Bank (Ohio) Marietta, Ohio $163M AUM 18.72% 1-Year Est. Return
PCR
Potrero Capital Research San Francisco, California $163M AUM 79.07% 1-Year Est. Return
BCM
Basso Capital Management Stamford, Connecticut $163M AUM 21.95% 1-Year Est. Return
IVGAI
Index Venture Growth Associates IV St. Helier, Jersey $163M AUM 54.88% 1-Year Est. Return
CC
Cannell Capital Alta, Wyoming $163M AUM 40.62% 1-Year Est. Return
TCGDR
TB Capital Gestao de Recursos Rio De Janeiro $163M AUM 20.86% 1-Year Est. Return
IPWA
International Private Wealth Advisors San Diego, California $163M AUM 16.99% 1-Year Est. Return

Omega Fund Management's Q2 2024 Portfolio in Review

As of Q2 2024, Omega Fund Management held 12 positions worth $135M, down 13% from $155M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Omega Fund Management's Q2 2024 filing shows 1 new, 3 reduced and 1 closed positions. Its largest new stake was Alumis Inc: 653,225 shares worth $8.69M. The largest sale was Replimune Group, an estimated $3.76M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Omega Fund Management's largest Q2 2024 buy was Alumis Inc: 653,225 shares worth $8.69M.
  • Omega Fund Management's biggest Q2 2024 reduction was Replimune Group, cutting an estimated $3.76M.
  • Omega Fund Management fully exited Kronos Bio in Q2 2024, selling an estimated $1.24M.
  • Omega Fund Management's ten largest holdings make up 100% of its $135M portfolio in Q2 2024.
  • Omega Fund Management opened 1 new position and closed 1 in Q2 2024.
  • Omega Fund Management's portfolio value fell 13% quarter-over-quarter to $135M.

Based on Omega Fund Management's 13F filing for Q2 2024, filed 14 Aug 2024.